<DOC>
	<DOCNO>NCT01147133</DOCNO>
	<brief_summary>Clopidogrel essential prevention vascular event patient percutaneous coronary intervention ( PCI ) . Most current knowledge clopidogrel originate clinical investigation use Plavix®/Iscover® Sanofi-Aventis original formulation clopidogrel-bisulphate . However , patency Plavix® expire November 2009 Hungary , several generic clopidogrel introduce market . Some generic use original bisulphate formulation , others besylate salt clopidogrel . Despite difference clopidogrel-salts , different carrier might also modulate pharmacokinetic/pharmacodynamic profile drug . As consequence impaired antiplatelet potency might devastate , include stent thrombosis , investigator seek compare generic clopidogrel original blister different assay platelet aggregation .</brief_summary>
	<brief_title>Comparison Generic Original Formulation Clopidogrel</brief_title>
	<detailed_description>Clopidogrel essential prevention vascular event patient percutaneous coronary intervention ( PCI ) . Most current knowledge clopidogrel originate clinical investigation use Plavix®/Iscover® Sanofi-Aventis original formulation clopidogrel-bisulphate . However , patency Plavix® expire November 2009 Hungary , several generic clopidogrel introduce market . Some generic use original bisulphate formulation , others besylate salt clopidogrel . Despite difference clopidogrel-salts , different carrier might also modulate pharmacokinetic/pharmacodynamic profile drug . As consequence impaired antiplatelet potency might devastate , include stent thrombosis , investigator seek compare generic clopidogrel original blister different assay platelet aggregation . In prospective , cross-over , open-label , unblinded study investigator aim compare platelet activation aggregation Plavix® generic clopidogrel .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>Patients maintenance phase PCI receive 1x75 mg clopidogrel 1x100 mg aspirin No plan interruption antiplatelet therapy next 1 month Informed consent Oral anticoagulant therapy Contraindication aspirin clopidogrel Planned interruption antiplatelet therapy next month</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Platelet aggregation</keyword>
	<keyword>Generic</keyword>
	<keyword>Clopidogrel</keyword>
	<keyword>Comparison</keyword>
	<keyword>VASP-PRI</keyword>
</DOC>